---
title: Prof Goh Boon Cher
permalink: /leaders/prof-goh-boon-cher/
description: ""
third_nav_title: Executive Committee
variant: tiptap
---
<div class="isomer-image-wrapper"><img style="width:150px" height="auto" width="100%" src="/images/Leaders/prof-goh-boon-cher.png"></div><h5>Affiliations</h5><hr><p><strong>Singapore Translational Cancer Consortium</strong></p><ul data-tight="true" class="tight"><li><p>Cancer Clinical Trials and IMUs Platform Lead</p></li></ul><p><strong>National University of Singapore</strong></p><ul data-tight="true" class="tight"><li><p>Deputy Director, Cancer Science Institute of Singapore;&nbsp;</p></li><li><p>Yong Loo Lin Professor in Medical Oncology</p></li></ul><p><strong>National University Health System</strong></p><ul data-tight="true" class="tight"><li><p>Senior Consultant (Hematology-Oncology), National University Cancer Institute, Singapore</p></li></ul><h5>Profile</h5><hr><p><strong>Professor Goh Boon Cher</strong> received his undergraduate medical education at the National University of Singapore, and joined the Department of&nbsp;Hematology-Oncology, NUH where he completed fellowship in medical oncology, and completed a National Medical Research Council fellowship in clinical pharmacology and phase I clinical trials at the University of Chicago. Professor Goh has&nbsp;established&nbsp;himself as a leading clinician scientist in clinical pharmacology and cancer drug development, and currently serves on several institutional and national research portfolios. He has contributed much to the development of a clinical trial research infrastructure at the NCIS, one of the largest clinical research groups in Singapore, and chaired the Cancer Therapeutics Research Group, an Asia Pacific cancer research group. As a clinician, Professor Goh is well&nbsp;established&nbsp;in the fields of head and neck/lung cancer. As a senior clinician and scientist, he has mentored many clinical oncology and pharmacology fellows, and has been awarded senior clinician scientist from the Biomedical Research Council and the National Medical Research Council since 2005. In addition, he has been competitive in being awarded research grants as principal investigator of both individual project grants and infrastructure grants. Beyond cancer therapeutics, he is also widely published in pharmacogenetics, studying how human genetics affect drug response. Internationally, as a key opinion leader, he has served on advisory boards of several pharmaceutical companies advising on drug development of very novel&nbsp;drugs, and&nbsp;has served on editorial boards of important journals like the Journal of Clinical Oncology and Annals of Oncology. As a responsible member of clinical research, he has also espoused principles of ethics, and served for several terms as Chairman of the Domain Specific Research Board.&nbsp;</p><p><strong>Selected Publications</strong>&nbsp;&nbsp;</p><hr><ul><li><p><a href="https://pubmed.ncbi.nlm.nih.gov/30918950/" rel="noopener noreferrer nofollow" target="_blank">Hellmann MD, Kim TW, Lee CB,&nbsp;</a><strong><a href="https://pubmed.ncbi.nlm.nih.gov/30918950/" rel="noopener noreferrer nofollow" target="_blank">Goh BC</a></strong><a href="https://pubmed.ncbi.nlm.nih.gov/30918950/" rel="noopener noreferrer nofollow" target="_blank">, Miller WH, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann Oncol. 2019 30(7):1134-1142</a>&nbsp;</p></li><li><p><a href="https://pubmed.ncbi.nlm.nih.gov/28841236/" rel="noopener noreferrer nofollow" target="_blank">Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP,&nbsp;</a><strong><a href="https://pubmed.ncbi.nlm.nih.gov/28841236/" rel="noopener noreferrer nofollow" target="_blank">Goh BC</a></strong><a href="https://pubmed.ncbi.nlm.nih.gov/28841236/" rel="noopener noreferrer nofollow" target="_blank">, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017;123(24):4851.</a>&nbsp;</p></li><li><p><a href="https://pubmed.ncbi.nlm.nih.gov/27681866/" rel="noopener noreferrer nofollow" target="_blank">Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartono S, Thng CH, Huynh H, Lim KT, Toh HC,&nbsp;</a><strong><a href="https://pubmed.ncbi.nlm.nih.gov/27681866/" rel="noopener noreferrer nofollow" target="_blank">Goh BC</a></strong><a href="https://pubmed.ncbi.nlm.nih.gov/27681866/" rel="noopener noreferrer nofollow" target="_blank">, Choo SP. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol 2016;27(12):2210.</a>&nbsp;</p></li><li><p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325427/" rel="noopener noreferrer nofollow" target="_blank">Wong AL, Sundar R, Wang TT, Ng TC, Zhang B, Tan SH, Soh TI, Pang AS, Tan CS, Ow SG, Wang L, Mogro J, Ho J, Jeyasekharan AD, Huang YQ, Thng CH, Chan CW, Hartman M, Iau P, Buhari SA,&nbsp;</a><strong><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325427/" rel="noopener noreferrer nofollow" target="_blank">Goh BC</a></strong><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325427/" rel="noopener noreferrer nofollow" target="_blank">, Lee SC. Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget 2016 Aug</a>&nbsp;</p></li><li><p><a href="https://pubmed.ncbi.nlm.nih.gov/25609248/" rel="noopener noreferrer nofollow" target="_blank">A. L. Wong,&nbsp; R. A. Soo, D. S. Tan, S. C.&nbsp; Lee,&nbsp; J. S. Lim, P. C. Marban, L. R. Kong, Y. J. Lee, L. Z. Wang, W. L. Thuya, R. Soong, M. Q. Yee, T. M. Chin, M. T. Cordero, B. R. Asuncion, B. Pang, S. Pervaiz, JL Hirpara, A. Sinha, W. W. Xu, M. Yuasa, T. Tsunoda, M. Motoyama, T. Yamauchi and&nbsp;</a><strong><a href="https://pubmed.ncbi.nlm.nih.gov/25609248/" rel="noopener noreferrer nofollow" target="_blank">B. C. Goh</a></strong><a href="https://pubmed.ncbi.nlm.nih.gov/25609248/" rel="noopener noreferrer nofollow" target="_blank">. Phase I and biomarker study of a novel inhibitor of STAT3 phophorylation, OPB-51602 in patients with refractory solid cancers. Ann Oncol 2015;26(5):998-1005.</a>&nbsp;</p></li><li><p><a href="https://pubmed.ncbi.nlm.nih.gov/23930212/" rel="noopener noreferrer nofollow" target="_blank">Tsao A, Hui EP, Juergens R, Marur S, Huat TE,&nbsp;</a><strong><a href="https://pubmed.ncbi.nlm.nih.gov/23930212/" rel="noopener noreferrer nofollow" target="_blank">Cher GB</a></strong><a href="https://pubmed.ncbi.nlm.nih.gov/23930212/" rel="noopener noreferrer nofollow" target="_blank">, Hong RL, Hong WK, Chan AT. Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. Cancer Med. 2013 Jun;2(3):351-9.</a>&nbsp;</p></li><li><p><a href="https://pubmed.ncbi.nlm.nih.gov/21712450/" rel="noopener noreferrer nofollow" target="_blank">Lim WT, Ng QS, Percy I, Leong SS, Singh O, Chowbay B, Gao F, Thng CH,&nbsp;</a><strong><a href="https://pubmed.ncbi.nlm.nih.gov/21712450/" rel="noopener noreferrer nofollow" target="_blank">Goh BC</a></strong><a href="https://pubmed.ncbi.nlm.nih.gov/21712450/" rel="noopener noreferrer nofollow" target="_blank">, Tan DS, Koh TS, Toh CK, Tan EH. Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma. Clin Cancer Res 2011;17(16):5481-9.</a>&nbsp;</p></li><li><p><a href="https://pubmed.ncbi.nlm.nih.gov/19705063/" rel="noopener noreferrer nofollow" target="_blank">Chan D, Yeo WL, Tiemsim Cordero M, Wong CI, Chuah B, SooR, Tan SH, Lim SE,&nbsp;</a><strong><a href="https://pubmed.ncbi.nlm.nih.gov/19705063/" rel="noopener noreferrer nofollow" target="_blank">Goh BC</a></strong><a href="https://pubmed.ncbi.nlm.nih.gov/19705063/" rel="noopener noreferrer nofollow" target="_blank">, Lee SC. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Invest New Drugs 2010;28(6):859-62.</a>&nbsp;</p></li><li><p><a href="https://pubmed.ncbi.nlm.nih.gov/19720910/" rel="noopener noreferrer nofollow" target="_blank">Chiung-Ing Wong, Tong-San Koh, Ross Soo, Septian Hartono, Choon-Hua Thng, Evelyn McKeegan, Wei-Peng Yong, Chien-Shing Chen, Soo-Chin Lee, John Wong, Robert Lim, Norita Sukri, Siew-Eng Lim, Ai-Bee Ong, Joyce Steinberg, Neeraj Gupta, Rajendra Pradhan, Rod Humerickhouse,&nbsp;</a><strong><a href="https://pubmed.ncbi.nlm.nih.gov/19720910/" rel="noopener noreferrer nofollow" target="_blank">Boon-Cher Goh</a></strong><a href="https://pubmed.ncbi.nlm.nih.gov/19720910/" rel="noopener noreferrer nofollow" target="_blank">. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009;27(28):4718-4726.</a>&nbsp;</p></li><li><p><a href="https://pubmed.ncbi.nlm.nih.gov/17909805/" rel="noopener noreferrer nofollow" target="_blank">Yong WP, Wang LZ, Tham LS, Wong CI, Lee SC, Soo R, Sukri N, Lee HS,&nbsp;</a><strong><a href="https://pubmed.ncbi.nlm.nih.gov/17909805/" rel="noopener noreferrer nofollow" target="_blank">Goh BC</a></strong><a href="https://pubmed.ncbi.nlm.nih.gov/17909805/" rel="noopener noreferrer nofollow" target="_blank">.&nbsp;A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Cancer Chemother Pharmacol 2007 Oct 2 (epub)</a>&nbsp;</p></li></ul><hr><p></p>